Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal Mitoxantrone + CVP (CMOP) in Untreated PTCL
NCT04548700Phase 1Terminated
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Dec 2020
- Primary completion
- Jun 2023
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of mitoxantrone hydrochloride liposome in peripheral T-cell lymphoma (PTCL), sponsored by CSPC ZhongQi Pharmaceutical Technology. Primary endpoints: Incidence of Dose Limited Toxicities and Incidence of Adverse Events and Serious Adverse Events up to 24 weeks. Started Dec 2020; status: terminated.
02
Drugs
mitoxantrone hydrochloride liposome
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT04548700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04548700.